Orgovyx from Myovant Sciences is a gonadotropin-releasing hormone receptor antagonist that is FDA indicated to treat adults with advanced prostate cancer. FDA approved the drug in December 2020. In a press release, Richard Pazdur, FDA’s acting director of the Office of Oncologic Diseases, noted that ORGOVYX is “the first oral drug in this class and it…